NCT06801886View on ClinicalTrials.gov

Silymarin's Advantage on Graft Effectiveness

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Posttransplant Diabetes MellitusAcute Graft RejectionBiopsy Proven Acute RejectionAntibody Mediated Rejection of Kidney TransplantArterial Hypertension, Chronic Kidney Disease
Interventions
DRUG

Silymarine supplementation

900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.

OTHER

Placebo Supplementation

Placebo supplementation during the early post-transplant period (30 days) under standard treatment

Trial Locations (1)

036 01

University Hospital Martin, Martin

All Listed Sponsors
lead

University Hospital, Martin

OTHER